CT 04
Alternative Names: CT-04Latest Information Update: 16 Feb 2023
At a glance
- Originator Captor Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Colorectal cancer
Most Recent Events
- 06 Jan 2023 CT 04 is available for licensing as of 06 Jan 2023. https://www.captortherapeutics.com/our-approach
- 06 Jan 2023 Early research in Colorectal cancer in Poland (unspecified route), before January 2023 (Captor Therapeutics pipeline, January 2023)